Speaker Profile

Ph.D., Director of Engineering, OpenCell

Biography
Michael is an engineer and entrepreneur with over a decade of experience developing microfluidic and ultrasound devices for life sciences applications. Serving as Director of Engineering, he spearheads the company’s effort to scale the POROS platform for gene delivery in hard-to-transfect cell lines to realize practical allogenic CAR-T therapies and to optimize current nanomaterial delivery methods. Prior to joining OpenCell Technologies, he received his Ph.D. in Mechanical Engineering from Washington University in St. Louis while creating innovative solutions for cancer detection, cell isolation, and in vitro biomimicry—publishing 30+ peer-reviewed manuscripts and multiple patents. His inventions range from the use of acoustics to manipulate cells, the synthesis of antibody-drug conjugates in microfluidic channels, and methods for monitoring micro-bioelectrochemical cell devices. He is committed to translating his research experience from the bench to tangible global healthcare solutions.


 Session Abstract – PMWC 2023 Silicon Valley

Track 1 - January 25 9.00 A.M.-3.00 P.M.


Track Co-Chairs:
Yael Weiss, Mahzi
Peter Marks, FDA

  • Welcome and Opening by Track Chairs: Yael Weiss, Mahzi & Peter Marks, FDA
  • Patient Driven Therapies: The Challenges and Successes (PANEL)
    Chair: Yael Weiss, Mahzi
    - Allyson Berent, Angelman Foundation
    - Terry Pirovolakis, CureSPG50
  • From Bench to Bedside - Biomarkers, Natural History Studies, Animal Models (PANEL)
    Chair: Peter Marks, FDA
    - Emil Kakkis, Ultragenyx
    - Alysson Muotri, UCSD
    - Nasha Fitter, Invitae
  • Commercialization - Moving from Rare to Common (PANEL)
    Chair: John Maraganore, Alnylam Pharmaceuticals
    - Shankar Ramaswamy, Kriya
    - Rahul Singhvi, Resilience
    - Andrew Lo, MIT
    - Mark Harrison, University of British Colombia
  • Future Modalities (PANEL)
    Chair: Shannon Muir, CIAPM
    - Nadav Ahituv, UCSF
    - Amber Salzman, Epic Bio
    - Ben Oakes, Scribe Therapeutics
  • Bioethics & Ethical Implications in Cell and Gene Therapies
    - Hank Greely, Stanford
    - Hana El-Samad, UCSF